Browse > Article

Comparison of Pharmacokinetics and Safety Between Coadministration of Cilostazol and Ginkgo Biloba Extract and Administration of a Fixed-Dose Combination  

Jeon, Hye-Won (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Yi, So-Jeong (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Kim, Sung-Eun (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Kim, Bo-Hyung (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Lim, Kyoung-Soo (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Lee, Bong-Yong (Life Science R&D Center, SK Chemicals Co., Ltd)
Yu, Kyung-Sang (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Shin, Sang-Goo (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Jang, In-Jin (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Publication Information
Journal of Korean Society for Clinical Pharmacology and Therapeutics / v.18, no.1, 2010 , pp. 5-14 More about this Journal
Abstract
Background: Cilostazol is widely used as an antiplatelet drug in patients with intermittent claudication and peripheral arterial disease. Ginkgo biloba extract is prescribed in the management of circulatory disorders in peripheral arteries. Thus a fixed-dose combination of the two drugs has been under clinical development. The pharmacokinetics of cilostazol and safety profiles were compared between coadministration of cilostazol and Ginkgo biloba extract, and that of a fixed-dose combination of the two drugs. Methods: A randomized, open-label, single-dose, two-treatment, two-period, two-sequence crossover study was conducted in 26 healthy male volunteers. Subjects were administered cilostazol 100 mg and Ginkgo biloba extract 80 mg concomitantly and a fixed-dose combination of the two drugs with a 7-day washout in between. Plasma concentrations of cilostazol were determined by liquid chromatography-tandem mass spectrometry. Safety profiles were assessed by physical examinations, electrocardiograms, vital signs, laboratory testings, and monitoring adverse events. Results: Median $T_{max}$ of cilostazol was 3.0 and 4.0 hours after administration of cilostazol and Ginkgo biloba extract concomitantly and fixed-dose combination of the two drugs, respectively. The geometric mean ratio (90% confidence intervals) of the fixed dose combination to the coadministration for $C_{max}$ was 0.95 (0.87-1.05) and that for $AUC_{last}$ was 1.03 (0.96-1.10). The most frequently reported adverse event was headache, reported by 14 subjects. There was no difference of adverse event occurrences between two treatment groups. No serious adverse events were reported. Conclusion: Pharmacokinetics of cilostazol and safety were comparable between coadministration of cilostazol and Ginkgo biloba extract, and administration of a fixed-dose combination of the two drugs.
Keywords
Cilostazol; Ginkgo biloba extract; Pharmacokinetics; Comparative studies;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Igawa T, Tani T, Chijiwa T, Shiragiku, T, Shimidzu, S, Kawamura, K, Kato, S, Unemi, F, Kimura, Y. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res, 1990;57:617-623.   DOI   ScienceOn
2 Chapman TM, Goa KL. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs, 2003;3:117-138.   DOI   ScienceOn
3 Spinnewyn B, Blavet N, Clostre F, Bazan N, Braquet P. Involvement of platelet-activating factor (PAF) in cerebral post-ischemic phase in Mongolian gerbils. Prostaglandins, 1987;34:337-349.   DOI   ScienceOn
4 Kim TE, Kim BH, Kim J, Kim KP, Yi S, Shin HS, Lee YO, Lee KH, Shin SG, Jang IJ, Yu KS. Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. Clin Ther, 2009;31:2249-2257.   DOI   ScienceOn
5 Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. Geneva: WHO Technical Report Series, No. 937; 2006.
6 Birk S, Kruuse C, Petersen KA, Tfelt-Hansen P, Olesen J. The headache-inducing effect of cilostazol in human volunteers. Cephalalgia, 2006;26:1304-309.   DOI   ScienceOn
7 Ryu KH, Han HY, Lee SY, Jeon SD, Im GJ, Lee BY, Kim K, Lim KM, Chung JH. Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time. Thromb Res, 2009;124:328-334.   DOI   ScienceOn
8 Bramer SL, Forbes WP, Mallikaarjun S. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet, 1999;37 Suppl 2:1-11.   DOI
9 Pletal${\circledR}$ (NDA 20-863/S-021) Drug Label. In: OTSUKA; 2007.
10 Diamond BJ, Shiflett SC, Feiwel N, Matheis RJ, Noskin O, Richards JA, Schoenberger NE. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil, 2000;81:668-678.
11 Guidelines for registration of fixed-dose combination medicinal products. Geneva: WHO Technical Report Series, No.929; 2005.
12 Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol, 1992;34:352-358.   DOI   ScienceOn
13 Jacobs BP, Browner WS. Ginkgo biloba: a living fossil. Am J Med, 2000;108:341-342.   DOI   ScienceOn
14 Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002:CD003120.